Research location

Koshigaya

Saitama, Japan

Published trials30

Site observations31

Linked trials published30

Page1 / 1

Research activity in Koshigaya

Saitama, Japan

CureCurrent currently publishes aggregate city-level research activity for this location: 30 trials and 31 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Koshigaya

30 linked trials · page 1 of 1

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive DisorderNCT07204314 · 2025-10-01 · 1 site observation

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068 · 2025-08-06 · 1 site observation

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg PenNCT04940065 · 2021-06-30 · 1 site observation

Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWSNCT04697381 · 2021-02-09 · 1 site observation

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsNCT04593927 · 2020-10-28 · 2 site observations

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)NCT04191096 · 2020-02-12 · 1 site observation

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)NCT03834493 · 2019-07-28 · 1 site observation

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)NCT03834506 · 2019-05-02 · 1 site observation

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)NCT03834519 · 2019-05-02 · 1 site observation

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.NCT02703636 · 2016-05-09 · 1 site observation

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaNCT02554786 · 2015-12-29 · 1 site observation

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01 · 1 site observation

Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid ArthritisNCT01850966 · 2012-09-12 · 1 site observation

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential HypertensionNCT01615198 · 2012-08-01 · 1 site observation

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)NCT01614886 · 2012-07-01 · 1 site observation

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential HypertensionNCT01599104 · 2012-06-01 · 1 site observation

Dose Finding Study for QAW039 in AsthmaNCT01437735 · 2011-08-01 · 1 site observation

Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionNCT01237873 · 2011-01-01 · 1 site observation

Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's DiseaseNCT01251718 · 2010-12-01 · 1 site observation

Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-NCT01129596 · 2010-06-10 · 1 site observation

Long-term Safety Study of Vildagliptin in Patients With Type 2 DiabetesNCT01159249 · 2010-06-01 · 1 site observation

Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mgNCT00919477 · 2009-05-01 · 1 site observation

Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD StudyNCT00768560 · 2008-01-01 · 1 site observation

Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is InsufficientNCT00443456 · 2007-05-01 · 1 site observation

A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is InsufficientNCT00415623 · 2007-01-01 · 1 site observation

Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic PatientsNCT00252785 · 2005-10-01 · 1 site observation

Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 DiabetesNCT00419484 · 2004-03-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.